Syntec Optics (OPTX) Q3 2024 earnings summary

Executive summary

• Net sales for Q3 2024 increased 19.2% year-over-year to $7.9 million, driven by growth in communications, defense, medical, and data center optics, offset by a decline in consumer sales.

• Strategy focuses on leading large, overlooked light-enabled markets with a diverse product portfolio for blue-chip customers, leveraging operational strengths and a solid financial foundation.

• Emphasis on innovation, manufacturing expertise, and proprietary technologies to maintain competitive advantage.

• General and administrative expenses rose 31.4% year-over-year in Q3 2024, mainly due to higher salaries and costs for future product launches.

• The company completed a business combination in November 2023, resulting in a reverse recapitalization.

Financial highlights

• Q3 2024 net sales were $7.86 million, up 19% year-over-year and 12.3% sequentially, but below guidance due to a new product move-out.

• Adjusted EBITDA for Q3 2024 was $1.10 million, down from $1.32 million in Q2 2024 and $1.30 million in Q3 2023, impacted by higher G&A expenses.

• Gross profit for Q3 2024 was $1.8 million, nearly flat year-over-year, with gross margin at 23%.

• Net income for Q3 2024 was negative $13,289 ($0.00 per share), compared to $0.3 million in Q2 2024 and $0.4 million in Q3 2023.

• Cash at September 30, 2024: $476,784, down from $2.2 million at year-end 2023.

Outlook and guidance

• Q4 2024 revenue expected between $7.4–$9.0 million, with gross margin stable or slightly improving.

• Positive net income is forecast for Q4 2024, with continued growth in communications, medical, and defense markets.

• First quarter 2025 expected to see further strength from communications and biomedical, with new defense product launches.

• New product launches in disposable optics and biomedical nano-precision optics expected to drive growth in 2025 and 2026.

• Plans for further automation and expansion of production capacity at the Rochester, NY facility.